Endocanna Inc Receives Investment From Heritage Cannabis (CNSX:CANN) For DNA Healthcare Applications
Len May, CEO of Endocanna Health, Inc and Clint Sharples, CEO of Heritage Cannabis (CNSX:CANN) join Midas Letter to discuss Endocanna’s DNA kit, that can enable health care professionals to identify an individual’s optimal cannabis formulation, based on their genetics. A deeper knowledge of how cannabis affects a person personally can minimize anxiety and time wasted, particularly for first-time users who make up the largest growing segment of the population in the United States. Furthermore, physicians can use this kit as a tool to determine how cannabis interacts with a person’s other medications to ensure efficacy as and enhance one’s experience. James shares the results of his own EndoDNA kit test, while discussing the applications of these findings.
James West: All right. I’m here now with Clint Sharples, CEO of Heritage Cannabis, and Len May, who’s the CEO of Endocanna Health, Inc. Gentlemen, welcome.
Clint Sharples: Good to see you, James.
Len May: Thanks for having us.
James West: Yeah, you bet. So Heritage has made an investment in Endocanna Health, which makes them a 30 percent invested investee.
Clint Sharples: Correct.
James West: And Len, why don’t we start with you: what does Endocanna Health do?
Len May: It helps to find the precise cannabis medicine for you as an individual. Our goal is to limit adverse reactions, basically. So, to help health care professionals find the ultimate cannabis recommendation for the individual, based on our genetics. So we use DNA as a road map to find an optimal formulation for an individual.
James West: So I took the test, I sent it away.
Len May: You did?
James West: And we came up with this screen, which I’m actually, risk of privacy notwithstanding, going to share with everybody.
Len May: Are you sure you want to share this with everyone? There is a lot of red on this.
James West: Well, I know! That’s so people will maybe understand why, you know, there’s an intensity here. No, no, I flatter myself. But okay, so now, I’ve got all of the screen shows me all these different sort of mental conditions or features of my personality under the influence of cannabis? Or, this is how I’m likely to respond when under the influence of THC, CBD, or both?
Len May: Yeah, it’s a great question. So we have it broken down into two separate categories: mental health and wellness, and physical health and wellness. So this is your genetic predisposition. If you were to consume cannabis, maybe that gene will be triggered. So this says, are you a higher risk, a moderate risk, or a low risk. So, to give you an example, like anxiety, it says a high risk of anxiety. So the anxiety, you may be prone to a quicker fight or flight response than the average population. And, by the way, high dose of THC may trigger that response in you, and other terpene profiles.
So we try to mitigate that to give you more of an optimal experience with cannabis.
James West: Right. So I happen to know that high THC levels do, in fact, induce a high level of anxiety in me at times. So I could use this report if I was seeking cannabis as a treatment option for whatever condition a doctor might have recommended, and I can have this test done, and I can look at it and a health professional will interpret this and say, Well, you should probably not do too high a THC product absent a balancing level of CBD. Is that the value inherent in this entire proposition?
Len May: Yes, and even a step further. So if you click on one of the categories such as anxiety, we show you your genetic profile as it pertains to anxiety, which is called your genotype. Then we actually give you a formulation suggestion that is more optimal specifically to you, based on your DNA. So if you see it says, like, number six, for instance: if you click on any of those icons like right over here, it’ll pop open a page that will show you a formulation that is more optimal to you, based on your genetics.
And what we want to do is, we want to make sure that we do not trigger a negative experience, so you can have a much more optimal experience. So there’s cannabinoids, THC, CBD, but there’s also terpenes, which are the essential oil the plant produces. And when you mix the two together, they give you an effect.
James West: Well, this is really interesting. This is recommending very high CBD to THC ratio to a moderate CBD to THC ratio, which, since I’ve had this revelation myself over a lot of trial and error – I mean, years’ worth – this is exactly the level of, like – so I do CBD every day with almost no THC, just enough to have the entourage effect, have the THC work. And then recreationally, I might consider doing up to a 4 to 1 ratio, but CBD to THC, not the other way around like all the kids like.
Len May: Exactly, exactly.
James West: So, this is amazing. This is actually confirming what I have learned painfully through trial and error for years. So that’s great. Now, tell me: how do you monetize this?
Len May: So, we have a kit that we sell, which is a genetic kit. It comes in a box, you order it online at Endocannahealth.com, or it’s called an EndoDNA kit. Inside is a big Q-tip, a buccal swab. You swab this in your mouth, put it back in the box, ship it over to our lab, and it’s $199 USD. And then the other way that we monetize this, if somebody has taken any of the other genetic tests, like a 23AndMe, an Ancestry.com, Family Tree, any of the other ones, you can upload your raw data that you already own, and we’ll translate it in less than 30 seconds, and we monetize that, as well.
James West: Fantastic. So, Clint, tell me: how does this fit in with the asset mix of Heritage Cannabis?
Clint Sharples: Yeah, that’s a good question. When we were taking a look at this, if you go back about a year ago in cannabis, it became extraordinarily clear that, if all you were was a grower, you had a very finite life in this industry, or a very finite profit profile. When we were talking, we were deciding to get into formulations, get into extraction and various other things, but we also knew that innovation had to be at the forefront.
We went looking for ways that, what would be the introduction to people when they are starting to use cannabis? The largest-growing segment of the population of users of cannabis in the States are people doing first-time using, looking to how to accent their health requirements. And, at the very forefront of this, would be a kit like the DNA kit. Would have saved you a lot of time, a lot of anxiety. And been able to steer you in the right direction right away.
But not just you as a user; it would also help your physician or help whatever healthcare provider that you’re dealing with, to be able to guide them into a direction that would help you, not just in cannabis, but how it also interacts with your other medication, which, when Len was describing this to me when we first met, kind of light one off in my head, thinking, this is stuff that is absolutely required in this industry. Not enough is known about this, and by introducing this kit, it could lead to so many more options down the road, in particular, bringing people looking for more knowledge in how cannabis affects them personally, and leads into so many more things that Endocanna has been working on.
James West: Yeah, well, that makes perfect sense. So this is completely legal in Canada; there are no legal ramifications with this test?
Len May: No, not that I’m aware of. This is a, we don’t make any claims, and everything that we say here is supported by science. So we provide you the peer-reviewed essay link for any single thing that we post on our site.
James West: So this is all peer-reviewed science?
Len May: All peer-reviewed science.
James West: Okay, fantastic.
Len May: And, we also use some artificial intelligence deep learning. As new science becomes available, you know, lifetime updates. So if somebody is doing a clinical trial in Israel or in Canada or Australia, we get that information, we update your reports on an ongoing basis.
James West: Fantastic.
Len May: One of the things that Clint was saying, I just want to add to, because adverse effects and harmful drug to drug interactions is really key, because CBD and other cannabinoids can actually reduce the efficacy of your prescription medication. So if somebody’s taking a blood thinner medication and is also taking CBD, it can actually reduce or enhance that experience. So we need to know that we can stagger our CBD and our blood thinner medication. In order to know how long to pause, you look at your metabolic function, what type of metabolizer you are. We all metabolize things differently.
And our test will be able to pinpoint that, what type of metabolizer you are, as well.
James West: Cool. All right, so if viewers want to go and sign up for the test, where do they go?
Len May: Endocannahealth.com or endoDNA.com.
James West: Perfect. All right, gentlemen, that’s a great development for Heritage. I mean, that’s really impressive.
Clint Sharples: Fantastic. We’re excited.
James West: And I can’t wait to see how much uptake there is of this across the entire industry. But for people like me who really left cannabis alone because of the anxiety association over time, I mean, this is just a godsend. So, congratulations and thanks for joining me today.
Clint Sharples: Thanks, James.
Len May: Thank you. Appreciate it.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.